DX Cover Logo2



DXCover is a clinical stage liquid biopsy company developing tests for the early detection of multiple cancers, when treatment has a better chance to impact outcomes. The company has pioneered the early detection and identification of cancer employing infrared spectroscopy of circulating paDX Cover Image-omic biomarkers. The company has generated compelling clinical data with high accuracy detection of Stage I and Stage II cancers. Dxcover is based in Scotland, United Kingdom and is establishing operations in the USA.




ProductEarly Stage Cancer Diagnosis
Aim of fundingDevelopment
HMRC Advanced Assurance receivedYes
Envisaged investor exit4-5 Years
Targeted return4 x